<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VAGIFEM - estradiol tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Vagifem safely and effectively. See full prescribing information for Vagifem.<br>Vagifem<span class="Sup">®</span> (estradiol vaginal tablets)<br>Initial U.S. Approval: 1999</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, ENDOMETRIAL CANCER, BREAST CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<ul>
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3</a>) </span></li>
<li><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>, <a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>) </span></li>
<li>
<span class="Bold">The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) </span><span class="Bold">(<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>)</span>
</li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>)</span></li>
</ul>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<ul>
<li><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>, <a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>)</span></li>
<li><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, DVT, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>) </span></li>
<li>
<span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3</a></span>)</li>
<li><span class="Bold">The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, ENDOMETRIAL CANCER, BREAST CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<ul>
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3</a>) </span></li>
<li><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>, <a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>) </span></li>
<li>
<span class="Bold">The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) </span><span class="Bold">(<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>)</span>
</li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>)</span></li>
</ul>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<ul>
<li><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>, <a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>)</span></li>
<li><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, DVT, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>) </span></li>
<li>
<span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3</a></span>)</li>
<li><span class="Bold">The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Vagifem is an estrogen (estradiol) indicated for the treatment of <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (<a href="#i4i_indications_id_c486b721-594f-4019-a254-909428a40a9d">1</a>). </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Vagifem should be administered intravaginally:  </p>
<ul><li>1 tablet daily for 2 weeks, followed by 1 tablet twice weekly (for example, Tuesday and Friday) (<a href="#i4i_section_id_43497146-8abd-4e83-8e50-62c220ea3de4">2.2</a>)</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Vagifem 10 mcg tablet: One vaginal tablet contains 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol (<a href="#i4i_dosage_form_strength_id_4a484c55-dfe1-4dce-9c5e-ef95854f0876">3</a>) </li>
<li>Vagifem 25 mcg tablet: One vaginal tablet contains 25.8 mcg of estradiol hemihydrate equivalent to 25 mcg of estradiol (<a href="#i4i_dosage_form_strength_id_4a484c55-dfe1-4dce-9c5e-ef95854f0876">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<ul>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>)</li>
<li>Known, suspected, or history of breast cancer (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>, <a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3</a>)</li>
<li>Known or suspected estrogen-dependent neoplasia (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>, <a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3 </a>)</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or history of these conditions (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>, <a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>)</li>
<li>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>), or a history of these conditions (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>, <a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">5.2</a>) </li>
<li>Known liver dysfunction or disease (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>, <a href="#i4i_section_id_d0bcd36a-7532-4e52-99d1-bbd8636416f1">5.11</a>)</li>
<li>Known or suspected pregnancy (<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">4</a>, <a href="#i4i_pregnancy_id_50d9965b-8b81-43f5-acc2-90386880766a">8.1</a>)</li>
</ul>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#i4i_section_id_318f4fd8-0daa-4254-a0a9-32276461feec">5.5</a>)</li>
<li>Discontinue estrogen if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#i4i_section_id_9b1010c7-d89d-4b7d-b41d-8b22286fefd0">5.6 </a>, <a href="#i4i_section_id_8a40b827-c95e-4ce0-8906-60e8614ebe86">5.7 </a>, <a href="#i4i_section_id_a21ba8c2-a817-4083-8378-4fae4ea70db6">5.10</a>, <a href="#i4i_section_id_d0bcd36a-7532-4e52-99d1-bbd8636416f1">5.11 </a>)</li>
<li>The Vagifem applicator may cause <span class="product-label-link" type="condition" conceptid="4050826" conceptname="Abrasion of vagina">vaginal abrasion</span> (<a href="#i4i_section_id_8cee359e-e22b-41c3-928f-0dd0873bb3a3">5.17</a>)</li>
<li>Monitor thyroid function in women on thyroid replacement therapy (<a href="#i4i_section_id_43ff5778-9d30-4c93-9975-93c7d86db4ce">5.12 </a>, <a href="#i4i_section_id_9486ea9e-6dfb-4f51-9c40-7b5f867feb55">5.19</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In prospective, randomized, placebo-controlled, double-blind studies the most common adverse reactions (incidence ≥5 percent) were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, genital pruritis, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#i4i_section_id_c7112ad4-965c-4a70-96b8-4175f14e173d">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk at 1-888-824-4336 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism (<a href="#i4i_section_id_77b1134c-f931-4dd9-a42e-aa2242665d3d">7.1</a>) </li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing Women: Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk (<a href="#i4i_nursing_mothers_id_a06be369-cbbc-40fb-a4ff-3250d38b425e">8.3</a>)</li>
<li>Geriatric Use: An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women’s Health Initiative Memory ancillary studies of the Women’s Health Initiative (<a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, ENDOMETRIAL CANCER, BREAST CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dosing</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Risks From Systemic Absorption</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Malignant Neoplasms </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Gallbladder Disease </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Visual Abnormalities</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Elevated Blood Pressure</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span> </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Exacerbation of Other Conditions</a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Local <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">Abrasion</span></a></h2>
<h2><a href="#section-5.18" class="toc">5.18 Laboratory Tests</a></h2>
<h2><a href="#section-5.19" class="toc">5.19 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Study Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Metabolic Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Effects on Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Women’s Health Initiative Studies</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Women’s Health Initiative Memory Study</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Possible Serious Adverse Reactions with Estrogens</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Possible Less Serious But Common Adverse Reactions with Estrogens</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Instructions for Use of Applicator</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_e2c6dd5d-9f07-405d-943b-a09f559280f1"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, ENDOMETRIAL CANCER, BREAST CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span> </h1>
<p class="First"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span></p>
<p><span class="Bold">Endometrial Cancer</span></p>
<p><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[</span><span class="Italics"><a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">see Warnings and Precautions (5.3)</a></span><span class="Italics">].</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span><span class="Italics"> [<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">see Warnings and Precautions (5.2)</a><a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">,(5.4), </a>and <a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">Clinical Studies (14.2)</a>,<a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">(14.3)</a>].</span></span></p>
<p><span class="Bold">The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg], relative to placebo<span class="Italics"> [<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">see Warnings and Precautions (5.2)</a><a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">, </a>and <a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">Clinical Studies (14.2)</a>].</span></span></p>
<p><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics"> [<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">see Warnings and Precautions (5.4) </a></span>, <span class="Italics"><a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">Use in Specific Populations (8.5)</a>, and </span><span class="Italics"><a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">Clinical Studies (14.3)</a></span><span class="Italics">].</span></span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
<p><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics"><a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">[see Warnings and Precautions (5.2)</a><a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">,(5.4) </a>and </span><span class="Italics"><a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">Clinical Studies (14.2)</a>,<a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">(14.3)</a></span><span class="Italics">].</span></span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of DVT, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo <span class="Italics">[<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">see Warnings and Precautions (5.2)</a>, and </span><span class="Italics"><a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">Clinical Studies (14.2)</a></span><span class="Italics">].</span></span></p>
<p><span class="Bold">The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics"><a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">[ see Warnings and Precautions (5.4)</a></span>, <span class="Italics"><a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">Use in Specific Populations (8.5)</a>, and <a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">Clinical Studies (14.3)]</a>.</span></span></p>
<p><span class="Bold">Breast Cancer</span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer <span class="Italics">[</span><span class="Italics"><a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">see Warnings and Precautions (5.3),</a></span><span class="Italics">and </span><span class="Italics"><a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">Clinical Studies (14.2)</a></span><span class="Italics">].</span></span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.</span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c486b721-594f-4019-a254-909428a40a9d"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f336ac39-606a-4a6f-8197-f92f1f5ef398"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">Atrophic Vaginitis</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_7cc9569c-5dfe-4276-9412-b738b37992c3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a390f5cb-9f2c-44c3-b32a-2c79ccb3f350"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information </h2>
<p class="First">Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. </p>
<p>A woman without a uterus does not need a progestin. In some cases, however, hysterectomized women with a history of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> may need a progestin <span class="Italics"><a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">[see Warnings and Precautions (5.3)</a></span><span class="Italics">, <a href="#i4i_section_id_d55dd58f-acd1-47e5-a0f0-c6a0f5a309ed">5.15)</a>]</span>.</p>
<p>Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43497146-8abd-4e83-8e50-62c220ea3de4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dosing</h2>
<p class="First">Vagifem should be administered intravaginally using the supplied applicator: 1 tablet daily for 2 weeks, followed by 1 tablet twice weekly (for example, Tuesday and Friday). Generally, women should be started at the 10 mcg dosage strength.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_4a484c55-dfe1-4dce-9c5e-ef95854f0876"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Vagifem is a small, white, round, film-coated, bi-convex vaginal tablet containing 10 mcg or 25 mcg of estradiol. Each vaginal tablet is 6 mm in diameter and is administered in a disposable applicator.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Vagifem should not be used in women with any of the following conditions:</p>
<ul>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Known, suspected, or history of breast cancer</li>
<li>Known or suspected estrogen-dependent neoplasia</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or history of these conditions</li>
<li>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>), or a history of these conditions</li>
<li>Known liver dysfunction or disease</li>
<li>Known or suspected pregnancy </li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_8c0fbe1f-68a0-44aa-b8e7-526253f808fa"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6d00e67-6abe-4197-be36-2b29e54c5560"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Risks From Systemic Absorption</h2>
<p class="First">Vagifem is intended only for vaginal administration. Systemic absorption occurs with the use of Vagifem. The warnings, precautions, and adverse reactions associated with the use of systemic estrogen therapy should be taken into account.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) has been reported with estrogen-alone therapy. An increased risk of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, DVT, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogens with or without progestins should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (for example, personal history or family history of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> [VTE], <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></p>
<p>In the Women’s Health Initiative (WHI) estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year one and persisted <span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>].</span> Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogens should be discontinued immediately.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving CE (0.625 mg) versus those receiving placebo (18 versus 21 per 10,000 women-years).<span class="Sup">1</span></p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in all women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to placebo (33 versus 25 per 10,000 women-years) <span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>].</span> The increase in risk was demonstrated after the first year and persisted.<span class="Sup">1</span></p>
<p><span class="Italics">Coronary Heart Disease</span></p>
<p>In the WHI estrogen - alone substudy, no overall effect on coronary heart disease (CHD) events (defined as non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [MI], silent MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was reported in women receiving estrogen alone compared to placebo<span class="Sup">2</span><span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>.</p>
<p>Subgroup analysis of women 50 to 59 years of age suggests a statistically non-significant reduction in CHD events (CE 0.625 mg compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 women-years).<span class="Sup">1</span></p>
<p>In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of CHD events in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).<span class="Sup">1</span> An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>.</p>
<p>In postmenopausal women with documented heart disease (n=2,763), average age 66.7 years, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]) treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of the original HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE (0.625 mg) plus MPA (2.5 mg) group and the placebo group in HERS, HERS II, and overall.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> (VTE) </span></p>
<p>In the WHI estrogen-alone substudy, the risk of VTE (DVT and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> [PE]) was increased for women receiving daily CE (0.625 mg) compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years<span class="Sup">3 </span><span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>. Should a VTE occur or be suspected, estrogens should be discontinued immediately.</p>
<p>In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was observed during the first year and persisted<span class="Sup">4</span><span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]. </span> Should a VTE occur or be suspected, estrogens should be discontinued immediately.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Malignant Neoplasms </h2>
<p class="First"><span class="Italics">Endometrial Cancer</span></p>
<p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in women with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with an increased risk of 15- to 24-fold for 5 to 10 years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<p><span class="Italics">Breast Cancer</span></p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the Women’s Health Initiative (WHI) substudy of daily CE (0.625 mg). In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg) was not associated with an increased risk of invasive breast cancer <span class="Italics">[relative risk (RR) 0.80] <span class="Sup">5</span></span><span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>.</p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for estrogen plus progestin compared with placebo.<span class="Sup">6 </span>Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for estrogen plus progestin compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for estrogen plus progestin compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups <span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>.</p>
<p>Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</p>
<p>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.</p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
<p><span class="Italics">Ovarian Cancer</span></p>
<p>The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent nCI, 0.77-3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.<span class="Sup">7 </span>In some epidemiologic studies, the use of estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </h2>
<p class="First">In the estrogen-alone Women’s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, a population of 2,947 hysterectomized women aged 65 to 79 years was randomized to daily CE (0.625 mg) or placebo. </p>
<p>In the WHIMS estrogen-alone ancillary study, after an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent nCI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE alone versus placebo was 37 versus 25 cases per 10,000 women-years<span class="Sup">8 </span><span class="Italics"> [<a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">see Use in Specific Populations (8.5)</a>, and <a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">Clinical Studies (14.3)</a>]</span>.</p>
<p>In the WHIMS estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent nCI, 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years<span class="Sup">8</span><span class="Italics"> [<a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">see Use in Specific Populations (8.5)</a>, and <a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">Clinical Studies (14.3)</a>]</span>.</p>
<p>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent nCI, 1.19-2.60). Since both substudies were conducted in women aged 65 to 79 years, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics"> [<a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">see Use in Specific Populations (8.5)</a>, and <a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">Clinical Studies (14.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_318f4fd8-0daa-4254-a0a9-32276461feec"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Gallbladder Disease </h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b1010c7-d89d-4b7d-b41d-8b22286fefd0"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in women with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8a40b827-c95e-4ce0-8906-60e8614ebe86"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Visual Abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in women receiving estrogens. Discontinue medication pending examination if there is a sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0ef4051-4ee9-4a89-9703-d89274dea867"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</h2>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9ac4a6a-9ca3-4b4b-8a69-e444006906e2"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Elevated Blood Pressure</h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a21ba8c2-a817-4083-8378-4fae4ea70db6"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">In women with preexisting <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0bcd36a-7532-4e52-99d1-bbd8636416f1"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span> </h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43ff5778-9d30-4c93-9975-93c7d86db4ce"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ad46892-ebfa-4d5c-aa7d-eeff5084d761"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women with conditions that might be influenced by this factor, such as a cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f624552c-cd27-4bc7-9d1b-a6f75091f1b1"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d55dd58f-acd1-47e5-a0f0-c6a0f5a309ed"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span></h2>
<p class="First">A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55c0f78e-292e-40f5-81b7-ab39ee0e6a7f"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Exacerbation of Other Conditions</h2>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8cee359e-e22b-41c3-928f-0dd0873bb3a3"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Local <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">Abrasion</span></h2>
<p class="First">A few cases of local <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasion</span> induced by the Vagifem applicator have been reported, especially in women with severely atrophic vaginal mucosa.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3b14060-c0c7-456f-8f2a-8ea542b40049"></a><a name="section-5.18"></a><p></p>
<h2>5.18 Laboratory Tests</h2>
<p class="First">Serum follicle stimulating hormone and estradiol levels have not been shown to be useful in the management of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9486ea9e-6dfb-4f51-9c40-7b5f867feb55"></a><a name="section-5.19"></a><p></p>
<h2>5.19 Drug/Laboratory Test Interactions</h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</p>
<p>Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone as measured by protein-bound iodine (PBI), T<span class="Sub">4 </span>levels (by column or by radioimmunoassay) or T<span class="Sub">3 </span>levels by radioimmunoassay. T<span class="Sub">3 </span>resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4 </span>and free  T<span class="Sub">3 </span>concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</p>
<p>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</p>
<p>Increased plasma HDL and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentrations, increased triglyceride levels.</p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_996a8dad-effa-46a2-8527-e6106200342c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics"><a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">[see Boxed Warning, Warnings and Precautions (5.2)]</a></span>
</li>
<li>Endometrial Cancer <span class="Italics"><a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">[see Boxed Warning, Warnings and Precautions (5.3)]</a></span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7112ad4-965c-4a70-96b8-4175f14e173d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Study Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In a 12-month randomized, double-blind, parallel group, placebo-controlled study, a total of 309 postmenopausal women were randomized to receive either placebo or Vagifem 10 mcg tablets. Adverse events with an incidence of ≥5% in the Vagifem 10 mcg group and greater than those reported in the placebo group are listed in Table 1.</p>
<a name="id_d42cceac-5dc2-45ac-9fbd-0376b4f81756"></a><table border="single" width="437.000">
<caption><span>Table 1: Treatment-Emergent Adverse Events Reported at a Frequency of ≥5% and More Frequent in Women Receiving Vagifem 10 mcg</span></caption>
<col width="36.6%">
<col width="31.8%">
<col width="31.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top">
<p class="First"><span class="Bold">Body System</span></p>
<p> Adverse Event</p>
</td>
<td class="Botrule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Treatment</span></p>
<p>Number (%) of Women</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p>N = 103</p>
<p>n (%)</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Vagifem </span></p>
<p>N = 205</p>
<p>n (%)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Body As A Whole</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">2 (2)</td>
<td class="Botrule" align="center" valign="top">14(7)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Digestive System</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">11 (5)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Urogenital System</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Vulvovaginal Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule Rrule" align="center" valign="top">3 (3)</td>
<td class="Botrule" align="center" valign="top">17 (8)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Vulvovaginal Pruritis </td>
<td class="Botrule Rrule" align="center" valign="top">2 (2)</td>
<td class="Botrule" align="center" valign="top">16 (8)</td>
</tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top">N = Total number of women in study.<p class="First">n = Number of women who experienced adverse event.</p>
</td></tr>
</tbody>
</table>
<p>In a 12-week, randomized, double-blind, placebo-controlled study, 138 postmenopausal women were randomized to receive either placebo or Vagifem 25 mcg tablets. Adverse events with an incidence of ≥5% in the Vagifem 25 mcg group and greater than those reported in the placebo group are listed in Table 2.</p>
<a name="id_19e01b72-5619-47d5-b118-a7365d4e71fe"></a><table width="439.000">
<caption><span>Table 2: Treatment-Emergent Adverse Events Reported at a Frequency of ≥5% and More Frequent in Women Receiving Vagifem 25 mcg</span></caption>
<col width="36.7%">
<col width="31.7%">
<col width="31.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top">
<p class="First"><span class="Bold">Body System</span></p>
<p> Adverse Event</p>
</td>
<td class="Botrule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Treatment</span></p>
<p>Number (%) of Women</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p>N = 47</p>
<p>n (%)</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Vagifem</span></p>
<p>N = 91</p>
<p>n (%)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Body As A Whole</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td class="Botrule Rrule" align="center" valign="top">3 (6)</td>
<td class="Botrule" align="center" valign="top">8 (9)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">2 (4)</td>
<td class="Botrule" align="center" valign="top">6 (7)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3 (6)</td>
<td class="Botrule" align="center" valign="top">6 (7)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Respiratory System</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"> Upper Respiratory Tract</p>
<p> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (4)</td>
<td class="Botrule" align="center" valign="top">5 (5)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Urogenital System</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">Moniliasis Genital</span></td>
<td class="Botrule Rrule" align="center" valign="top">1 (2)</td>
<td class="Botrule" align="center" valign="top">5 (5)</td>
</tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top">N = Total number of women in study.<p class="First">n = Number of women who experienced adverse event.</p>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a052ec87-3e03-41b9-92db-c49d87b1ee1b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported during post approval use of Vagifem 25 mcg. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p><span class="Bold"><span class="Italics">Genitourinary System</span></span></p>
<p>Endometrial cancer, <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4058568" conceptname="Vaginal irritation">vaginal irritation</span>, <span class="product-label-link" type="condition" conceptid="4244072" conceptname="Vaginal pain">vaginal pain</span>, <span class="product-label-link" type="condition" conceptid="193261" conceptname="Vaginospasm">vaginismus</span>, <span class="product-label-link" type="condition" conceptid="4150042" conceptname="Vaginal ulcer">vaginal ulceration</span></p>
<p><span class="Bold"><span class="Italics">Breast</span></span></p>
<p>Breast cancer</p>
<p><span class="Bold"><span class="Italics">Cardiovascular</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span></p>
<p><span class="Bold"><span class="Italics">Gastrointestinal</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p><span class="Bold"><span class="Italics">Skin</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, erythematous/<span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">pruritic rash</span>, <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span></p>
<p><span class="Bold"><span class="Italics">Central Nervous System</span></span></p>
<p>Aggravated <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p><span class="Bold"><span class="Italics">Miscellaneous</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, drug ineffectiveness, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, blood estrogen increase</p>
<p>Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_b43e9370-3de3-4310-825f-6ee9e97d0845"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No drug- drug interaction studies have been conducted with Vagifem.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77b1134c-f931-4dd9-a42e-aa2242665d3d"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Metabolic Interactions</h2>
<p class="First"><span class="Italics">In-vitro</span> and <span class="Italics">in-vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's Wort (<span class="Italics">Hypericum perforatum</span>) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_90160af3-f9cd-4e25-97c7-0d982f2c6ac4"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_50d9965b-8b81-43f5-acc2-90386880766a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Vagifem should not be used during pregnancy <span class="Italics">[<a href="#i4i_contraindications_id_778c9dc8-c05e-45b1-aa24-6f06cbf79ce9">see Contraindications (4)</a>]</span>. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_a06be369-cbbc-40fb-a4ff-3250d38b425e"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Vagifem should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk. Detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen. Caution should be exercised when Vagifem is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_90379bad-8d28-4e6d-9f60-f8b070815366"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Vagifem is not indicated in children. Clinical studies have not been conducted in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Vagifem to determine whether those over 65 years of age differ from younger subjects in their response to Vagifem.</p>
<p><span class="Italics">The Women’s Health Initiative Study </span></p>
<p>In the Women’s Health Initiative (WHI) estrogen-alone substudy (daily conjugated estrogens 0.625 mg versus placebo), there was a higher relative risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women greater than 65 years of age <span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>.</p>
<p>In the WHI estrogen plus progestin substudy, there was a higher relative risk of nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women greater than 65 years of age <span class="Italics">[<a href="#i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80">see Clinical Studies (14.2)</a>]</span>.</p>
<p><span class="Italics">The Women’s Health Initiative Memory Study</span></p>
<p>In the Women’s Health Initiative Memory Study (WHIMS) of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the estrogen-alone and the estrogen plus progestin substudies when compared to placebo <span class="Italics">[<a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">see Clinical Studies (14.3)</a>]</span>.</p>
<p>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics">[<a href="#i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b">see Clinical Studies (14.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_daffa322-63c6-4dd0-952d-5788110bcab8"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Vagifem has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_701894d6-eadc-4a82-8e69-88774f899311"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of Vagifem has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_257e74c4-af1e-40e0-94bc-29d3ab2d6d64"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in women. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of Vagifem together with institution of appropriate symptomatic care. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_97aa311c-f9a3-44a2-ba4b-f749729948c7"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Vagifem 10 mcg (estradiol vaginal tablets) are small, white, film-coated tablets containing 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. Vagifem 25 mcg (estradiol vaginal tablets) are small, white, film-coated tablets containing 25.8 mcg of estradiol hemihydrate equivalent to 25 mcg of estradiol. Each tablet of Vagifem 10 mcg and 25 mcg contains the following excipients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each Vagifem tablet is 6 mm in diameter and is placed in a disposable applicator. Each tablet-filled applicator is packaged separately in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. Vagifem tablets are used intravaginally. When the tablet comes in contact with the vaginal mucosa, estradiol is released into the vagina.</p>
<p>Estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17β-diol. The chemical formula is C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2</span> • ½ H<span class="Sub">2</span>O with a molecular weight of 281.4.</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="Structural Formula for Vagifem" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_26d67e0e-ee60-4fad-99a5-65f3a09858fb"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_e83220b0-2b38-4cbb-940f-07f6adf87079"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_468ff4fd-7721-465e-81f2-ccab0e728192"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Currently, there are no pharmacodynamic data known for Vagifem.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_865870d3-7174-48b3-9d61-8ce31a0f67a1"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Estrogen drug products are well absorbed through the skin, mucous membranes, and the gastrointestinal (GI) tract. The vaginal delivery of estrogens circumvents first-pass metabolism.</p>
<p>In a single-center, randomized, open-label, multiple-dose, parallel group study conducted in 58 patients, Vagifem 10 mcg and 25 mcg demonstrated a mean estradiol (E2) C<span class="Sub">ave</span> at Day 83 of 5.5 pg/mL and 11.59 pg/mL, respectively after 12 weeks of treatment (see Tables 3 and 4).</p>
<a name="id_19f42be1-7ef6-4dac-9005-a79771506a18"></a><table width="0.000">
<caption><span>Table 3: Arithmetic Means of Estradiol (E2), Estrone (E1), and Estrone Sulfate (E1S) PK Parameters Following Multiple Doses of Vagifem 10 mcg</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd> CV: Coefficient of Variance for both AUC<span class="Sub">0-24 </span>and C<span class="Sub">ave(0-24)</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="left" colspan="10" valign="top">Uncorrected for baseline, N=29</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">E2</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">E1</td>
<td class="Botrule" align="center" colspan="3" valign="top">E1S</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AUC<span class="Sub">0-24</span></p>(h.pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">C<span class="Sub">ave (0-24)</span></p>(pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">%CV<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AUC<span class="Sub">0-24</span></p>(h.pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">C<span class="Sub">ave (0-24)</span></p>(pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">%CV<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AUC<span class="Sub">0-24</span></p>(h.pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">C<span class="Sub">ave (0-24)</span></p>(pg/mL)</td>
<td class="Botrule" align="left" valign="top">%CV<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Day 1</td>
<td class="Botrule Rrule" align="left" valign="top">242.08</td>
<td class="Botrule Rrule" align="left" valign="top">10.09</td>
<td class="Botrule Rrule" align="left" valign="top">33.02</td>
<td class="Botrule Rrule" align="left" valign="top">485.21</td>
<td class="Botrule Rrule" align="left" valign="top">20.22</td>
<td class="Botrule Rrule" align="left" valign="top">44.86</td>
<td class="Botrule Rrule" align="left" valign="top">5158.32</td>
<td class="Botrule Rrule" align="left" valign="top">214.93</td>
<td class="Botrule" align="left" valign="top">53.57</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Day 14</td>
<td class="Botrule Rrule" align="left" valign="top">176.49</td>
<td class="Botrule Rrule" align="left" valign="top">7.35</td>
<td class="Botrule Rrule" align="left" valign="top">43.69</td>
<td class="Botrule Rrule" align="left" valign="top">496.14</td>
<td class="Botrule Rrule" align="left" valign="top">20.67</td>
<td class="Botrule Rrule" align="left" valign="top">30.88</td>
<td class="Botrule Rrule" align="left" valign="top">6323.41</td>
<td class="Botrule Rrule" align="left" valign="top">263.48</td>
<td class="Botrule" align="left" valign="top">50.07</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Day 83</td>
<td class="Rrule" align="left" valign="top">132.04</td>
<td class="Rrule" align="left" valign="top">5.50</td>
<td class="Rrule" align="left" valign="top">59.69</td>
<td class="Rrule" align="left" valign="top">411.08</td>
<td class="Rrule" align="left" valign="top">17.13</td>
<td class="Rrule" align="left" valign="top">39.58</td>
<td class="Rrule" align="left" valign="top">3804.65</td>
<td class="Rrule" align="left" valign="top">158.53</td>
<td class="Botrule" align="left" valign="top">49.76</td>
</tr>
</tbody>
</table>
<a name="id_bb68bba6-2b6e-4d97-82fc-79c12da46058"></a><table width="0.000">
<caption><span>Table 4: Arithmetic Means of Estradiol (E2), Estrone (E1), and Estrone Sulfate (E1S) PK Parameters Following Multiple Doses of Vagifem 25 mcg</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>CV: Coefficient of Variance for both AUC<span class="Sub">0-24 </span>and C<span class="Sub">ave(0-24)</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="left" colspan="10" valign="top">Uncorrected for baseline, N=28 or 27</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">E2</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">E1</td>
<td class="Botrule" align="center" colspan="3" valign="top">E1S</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AUC<span class="Sub">0-24</span></p>(h.pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">C<span class="Sub">ave (0-24)</span></p>(pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">%CV <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AUC<span class="Sub">0-24</span></p>(h.pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">C<span class="Sub">ave (0-24)</span></p>(pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">%CV<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">AUC<span class="Sub">0-24</span></p>(h.pg/mL)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">C<span class="Sub">ave (0-24)</span></p>(pg/mL)</td>
<td class="Botrule" align="left" valign="top">%CV<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Day 1</td>
<td class="Botrule Rrule" align="left" valign="top">495.27</td>
<td class="Botrule Rrule" align="left" valign="top">20.64</td>
<td class="Botrule Rrule" align="left" valign="top">25.70</td>
<td class="Botrule Rrule" align="left" valign="top">567.07</td>
<td class="Botrule Rrule" align="left" valign="top">23.63</td>
<td class="Botrule Rrule" align="left" valign="top">28.96</td>
<td class="Botrule Rrule" align="left" valign="top">5738.32</td>
<td class="Botrule Rrule" align="left" valign="top">239.10</td>
<td class="Botrule" align="left" valign="top">47.72</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Day 14</td>
<td class="Botrule Rrule" align="left" valign="top">466.63</td>
<td class="Botrule Rrule" align="left" valign="top">19.44</td>
<td class="Botrule Rrule" align="left" valign="top">33.53</td>
<td class="Botrule Rrule" align="left" valign="top">662.94</td>
<td class="Botrule Rrule" align="left" valign="top">27.62</td>
<td class="Botrule Rrule" align="left" valign="top">24.36</td>
<td class="Botrule Rrule" align="left" valign="top">7725.90</td>
<td class="Botrule Rrule" align="left" valign="top">321.91</td>
<td class="Botrule" align="left" valign="top">43.67</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Day 83</td>
<td class="Rrule" align="left" valign="top">278.27</td>
<td class="Rrule" align="left" valign="top">11.59</td>
<td class="Rrule" align="left" valign="top">61.83</td>
<td class="Rrule" align="left" valign="top">500.06</td>
<td class="Rrule" align="left" valign="top">20.84</td>
<td class="Rrule" align="left" valign="top">34.99</td>
<td class="Rrule" align="left" valign="top">4110.84</td>
<td class="Rrule" align="left" valign="top">171.29</td>
<td class="Botrule" align="left" valign="top">51.38</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Distribution</span></p>
<p>The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.</p>
<p><span class="Italics">Excretion</span></p>
<p>Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p>
<p><span class="Italics">Use in Specific Populations</span></p>
<p>Geriatric Use: There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Vagifem to determine whether those over 65 years of age differ from younger subjects in their response to Vagifem.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Vagifem has not been studied.</p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of Vagifem has not been studied.</p>
<p><span class="Italics">Drug Interactions</span></p>
<p><span class="Italics">In-vitro</span> and <span class="Italics">in-vivo</span> studies have shown that estrogens are metabolized partially by CYP3A4. Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's Wort (<span class="Italics">Hypericum perforatum</span>) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_67864f74-51d3-4ebb-8548-861e917acf2c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_debf06ce-72dd-41a7-b21e-42b8bbd870ed"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_cc554577-7095-43ba-ab66-d4e929cfa37d"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64b51b0f-b7a0-4ec4-a6a7-d03e7ab4f339"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Effects on Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span></h2>
<p class="First"><span class="Bold">Vagifem 10 mcg</span></p>
<p>A 12-month double-blind, randomized, parallel group, placebo-controlled multicenter study was conducted in the U.S. and Canada to evaluate the efficacy and safety of Vagifem 10 mcg in the treatment of <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span> in 309 postmenopausal women between 46 and 81 years of age (mean age = 57.6 years) who at baseline identified their most bothersome symptom of <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span> from among six symptoms (<span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span>, vaginal and/or vulvar irritation/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, vaginal soreness, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span> and <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> associated with intercourse). Women inserted one tablet intravaginally each day for 14 days, then one tablet twice weekly for the remaining 50 weeks. The majority (92.9%) of the women were Caucasian (n=287), 3.2% were Black (n=10), 1.6% were Asian (n=5) and 2.2% were Other (n=7). All subjects were assessed for improvement in the mean change from baseline to Week 12 for co-primary efficacy variables of: a composite of most bothersome symptoms of <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span>; percentage of vaginal superficial cells and percentage of vaginal parabasal cells on a vaginal smear; and vaginal pH.</p>
<p><span class="Italics">Relief of Vaginal Symptoms</span></p>
<p>Vagifem 10 mcg was statistically superior to placebo in reducing the severity of a composite score of most bothersome symptoms associated with <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span> at Week 12 (see Table 5).</p>
<a name="id_6048d7f0-bded-491b-a1e0-db1d3bb8a868"></a><table border="single" width="444.000">
<caption><span>Table 5: Mean Change from Baseline to Week 12 in a Composite Score of Most Bothersome Symptoms Compared to Placebo – ITT Population<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>All randomized subjects who received at least one dose of study drug and had at least one post-baseline evaluation.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Vagifem 10 mcg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">ITT Population<a href="#footnote-3" class="Sup">*</a></span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">N</td>
<td class="Botrule Rrule" align="center" valign="top">93</td>
<td class="Botrule Rrule" align="center" valign="top">190</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Baseline mean</p>
<p>composite score</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.29</td>
<td class="Botrule Rrule" align="center" valign="top">2.35</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Change from baseline at Week 12 (LOCF)</td>
<td class="Botrule Rrule" align="center" valign="top">-0.84</td>
<td class="Botrule Rrule" align="center" valign="top">-1.20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">p-value versus Placebo</td>
<td class="Rrule" align="center" valign="top">---</td>
<td class="Botrule Rrule" align="center" valign="top">0.002</td>
</tr>
</tbody>
</table>
<p>Also demonstrated for Vagifem 10 mcg compared to placebo was a statistically significant increase in the percentage of superficial cells at Week 12 (13.2 percent compared to 3.8 percent for matching placebo, p&lt;0.001), a statistically significant decrease in parabasal cells at Week 12 (-37.0 percent compared to -9.3 percent for matching placebo, p&lt;0.001), and a statistically significant mean reduction between baseline and Week 12 in vaginal pH score (-1.3 compared to -0.4 for matching placebo, p&lt;0.001).</p>
<p>Endometrial safety was assessed by endometrial biopsy at the screening and final study visit. Of the 172 subjects in the Vagifem 10 mcg group who had a biopsy performed at end of study, 92 subjects had endometrial tissue that was atrophic or inactive and 73 subjects had no tissue or tissue insufficient for diagnosis. There was one case of adenocarcinoma grade 2 and one case of complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> without atypia. Three subjects exhibited <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> (two atrophic <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and one adenomyomatus type <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyp</span>) and two others had adenomyosis and an atypical epithelial proliferation.</p>
<p>Endometrial safety of Vagifem 10 mcg was additionally evaluated in a second, 12 month, open-label, multicenter safety study. Of the 297 subjects who had a biopsy performed at end of study, 183 subjects had endometrial tissue that was atrophic or inactive and 111 subjects had no tissue or tissue insufficient for diagnosis. There was one case of complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> without atypia. Two subjects exhibited <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>.</p>
<p><span class="Bold">Vagifem 25 mcg</span></p>
<p>A placebo-controlled comparison study was done in the U.S., in which 230 women were randomized to receive either placebo, Vagifem 25 mcg or 10 mcg estradiol vaginal tablets. Women inserted one tablet intravaginally each day for 14 days, then one tablet twice weekly for the remaining 10 weeks. All subjects were assessed for vaginal symptoms. Vagifem 25 mcg was superior to placebo in reducing the severity of a composite score of symptoms associated with <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span> (see Table 6).</p>
<p>An open-label, controlled comparison study was done in Canada in which 159 women were randomized to receive either Vagifem 25 mcg or a comparator drug. Two (2) grams of the comparator drug was given daily for 3 weeks, withheld for 1 week, then repeated cyclically (3 weeks on, 1 week off) for up to 24 weeks; Vagifem 25 mcg was administered daily for 2 weeks, then twice weekly for the remaining 22 weeks. In this study, subjects were assessed for relief of symptoms. Vagifem 25 mcg was equally effective as the approved comparator product at the 2.0 gm dose in the relief of symptoms.</p>
<a name="id_2a423631-c8a8-4763-8bbb-47669fa46589"></a><table width="0.000">
<caption><span>Table 6: Mean Change from Baseline to Week 7 and Week 12 in a Composite Score of Symptoms Compared to Placebo – ITT Population<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></caption>
<col>
<col>
<col>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>All randomized subjects who received at least one dose of study drug and had at least one post-baseline evaluation.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Vagifem 25 mcg</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">ITT Population<a href="#footnote-4" class="Sup">*</a></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">N</td>
<td class="Botrule Rrule" align="center" valign="top">47</td>
<td class="Botrule" align="center" valign="top">91</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Baseline mean</td>
<td class="Botrule Rrule" align="center" valign="top">1.93</td>
<td class="Botrule" align="center" valign="top">1.85</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Change from baseline at Week 7 (LOCF)</td>
<td class="Botrule Rrule" align="center" valign="top">-0.85</td>
<td class="Botrule" align="center" valign="top">-1.22</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Change from baseline at Week 12 (LOCF)</td>
<td class="Botrule Rrule" align="center" valign="top">-0.83</td>
<td class="Botrule" align="center" valign="top">-1.33</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">p-value versus Placebo – Week 7 (LOCF)</td>
<td class="Botrule Rrule" align="center" valign="top">---</td>
<td class="Botrule" align="center" valign="top">0.016</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">p-value versus Placebo – Week 12 (LOCF)</td>
<td class="Rrule" align="center" valign="top">---</td>
<td class="Botrule" align="center" valign="top">0.005</td>
</tr>
</tbody>
</table>
<p>In the placebo-controlled study endometrial biopsies in non-hysterectomized women at week 12 were performed on 86 subjects (Vagifem 25 mcg: 32 subjects, estradiol 10 mcg: 33 subjects, Placebo: 21 subjects). Of these, 3 subjects each from the Vagifem 25 mcg and placebo groups and 8 from the 10 mcg estradiol group had insufficient tissue samples. Among those with biopsies that yielded sufficient tissue, results were normal with the exception of one subject in the Vagifem 25 mcg group, who had a simple <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> without atypia. </p>
<p>In the open-label study comparing Vagifem 25 mcg with a comparator vaginal cream on 49 women in each treatment group, endometrial biopsies were obtained at the screening visit and at the end of treatment. At the end of the study (Week 24), all subjects in the Vagifem treatment group whose biopsies yielded sufficient tissue showed an atrophic endometrium with the exception of one subject who had a proliferative endometrium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_32781b1f-c98d-48f9-a835-8232a5f14a80"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Women’s Health Initiative Studies</h2>
<p class="First">The Women’s Health Initiative (WHI) enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of either the use of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease [(CHD) defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>], with invasive breast cancer as the primary adverse outcome studied. A “global index? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes. These substudies did not evaluate the effects of CE or CE plus MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p><span class="Italics">WHI Estrogen-Alone Substudy</span></p>
<p>The WHI estrogen-alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen alone in predetermined primary endpoints.</p>
<p>Results of the estrogen-alone substudy, which included 10,739 women (average age of 63 years, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other) after an average follow-up of 7.1 years, are presented in Table 7.</p>
<a name="id_82b4730e-37eb-4b42-b8e3-ea4d61b2a89d"></a><table width="443.000">
<caption><span>Table 7: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI 
                           </span></caption>
<col width="29.8%">
<col width="27.8%">
<col width="21.9%">
<col width="20.5%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Not included in "global index".</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Results are based on an average follow-up of 6.8 years.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Event</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Relative Risk</p>
<p>CE vs. Placebo</p>(95% nCI )</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">CE</p>
<p>n=5,310</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Placebo</p>n=5,429</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Absolute Risk per 10,000 Women-Years</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">CHD events<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> </p>
<p><span class="Italics">Non-fatal MI</span><a href="#footnote-5" class="Sup">*</a></p>
<span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.95 (0.78-1.16)</p>
<p><span class="Italics">0.91 (0.73-1.14)</span></p>
<span class="Italics">1.01 (0.71-1.43)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">54</p>
<p><span class="Italics">40</span></p>
<span class="Italics">16</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">57</p>
<p><span class="Italics">43</span></p>
<span class="Italics">16</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span><a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" valign="top">1.33 (1.05-1.68)</td>
<td class="Botrule Rrule" align="center" valign="top">45</td>
<td class="Botrule Rrule" align="center" valign="top">33</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Italics"> Ischemic</span><a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">1.55 (1.19-2.01)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">38</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">25</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><a href="#footnote-5" class="Sup">*</a> <span class="Sup">,</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.47 (1.06-2.06)</td>
<td class="Botrule Rrule" align="center" valign="top">23</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.37 (0.90-2.07)</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive breast cancer<a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.80 (0.62-1.04)</td>
<td class="Botrule Rrule" align="center" valign="top">28</td>
<td class="Botrule Rrule" align="center" valign="top">34</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Colorectal cancer<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.08 (0.75-1.55)</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.65 (0.45-0.94)</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">19</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><a href="#footnote-5" class="Sup">*</a> <span class="Sup">,</span><a href="#footnote-6" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.64 (0.44-0.93)</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>,<a href="#footnote-5" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-6" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.58 (0.47-0.72)</td>
<td class="Botrule Rrule" align="center" valign="top">35</td>
<td class="Botrule Rrule" align="center" valign="top">59</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> <a href="#footnote-5" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-6" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.71 (0.64-0.80)</td>
<td class="Botrule Rrule" align="center" valign="top">144</td>
<td class="Botrule Rrule" align="center" valign="top">197</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes,  <a href="#footnote-7" class="Sup">‡</a><span class="Sup">,</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.08 (0.88-1.32)</td>
<td class="Botrule Rrule" align="center" valign="top">53</td>
<td class="Botrule Rrule" align="center" valign="top">50</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Overall mortality<a href="#footnote-5" class="Sup">*</a><span class="Sup">,</span><a href="#footnote-6" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.04 (0.88-1.22)</td>
<td class="Botrule Rrule" align="center" valign="top">79</td>
<td class="Botrule Rrule" align="center" valign="top">75</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Global Index 
                                 </td>
<td class="Rrule" align="center" valign="top">1.02 (0.92-1.13)</td>
<td class="Rrule" align="center" valign="top">206</td>
<td class="Botrule Rrule" align="center" valign="top">201</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI “global index? that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.<span class="Sup">9</span> The absolute excess risk of events included in the “global index? was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality <span class="Italics">[see Boxed Warnings, and <a href="#i4i_warnings_precautions_id_8c0fbe1f-68a0-44aa-b8e7-526253f808fa">Warnings and Precautions(5)</a>].</span></p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years.</p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all subgroups of women examined, see Table 7.<span class="Sup">10</span></p>
<p>Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age showed in women 50-59 years of age, a non-significant trend toward reduced risk for CHD [HR 0.63<span class="Italics"> (95 percent CI 0.36-1.09)</span>] and overall mortality [HR 0.71<span class="Italics"> (95 percent CI, 0.46-1.11)</span>].</p>
<p><span class="Italics">WHI Estrogen Plus Progestin Substudy</span></p>
<p>The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the “global index.? The absolute excess risk of events included in the “global index? was 19 per 10,000 women-years.</p>
<p>For those outcomes included in the WHI “global index? that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breastcancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.</p>
<p>Results of the estrogen plus progestin substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 8. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</p>
<a name="id_08f1283f-d1dd-4ffd-b7a1-b0745c9f50d8"></a><table width="444.000">
<caption><span>Table 8: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years
                              <span class="Sup">,</span></span></caption>
<col width="29.7%">
<col width="27.7%">
<col width="21.8%">
<col width="20.7%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Not included in “global index?. </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Event</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Relative Risk</p>
<p>CE/MPA vs Placebo</p>(95% nCI)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">CE/MPA</p>
<p>n=8,506</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Placebo</p>n=8,102</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Absolute Risk per 10,000 Women-Years</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">CHD events</p>
<p><span class="Italics"> Non-fatal MI</span></p>
<span class="Italics"> CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1.23 (0.99-1.53)</p>
<p><span class="Italics">1.28 (1.00-1.63)</span></p>
<span class="Italics">1.10 (0.70-1.75)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">41</p>
<p><span class="Italics">31</span></p>
<span class="Italics">8</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">34</p>
<p><span class="Italics">25</span></p>
<span class="Italics">8</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></p>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1.31 (1.02-1.68)</p>
<span class="Italics">1.44 (1.09-1.90)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">33</p>
<span class="Italics">26</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">25</p>
<span class="Italics">18</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.95 (1.43-2.67)</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td class="Botrule Rrule" align="center" valign="top">2.13 (1.45-3.11)</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive breast cancer
                                 </td>
<td class="Botrule Rrule" align="center" valign="top">1.24 (1.01-1.54)</td>
<td class="Botrule Rrule" align="center" valign="top">41</td>
<td class="Botrule Rrule" align="center" valign="top">33</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Colorectal cancer</td>
<td class="Botrule Rrule" align="center" valign="top">0.61 (0.42-0.87)</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Endometrial cancer<a href="#footnote-8" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.81 (0.48-1.36)</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cervical cancer<a href="#footnote-8" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.44 (0.47-4.42)</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.67 (0.47-0.96)</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><a href="#footnote-8" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.65 (0.46-0.92)</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-8" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.71 (0.59-0.85)</td>
<td class="Botrule Rrule" align="center" valign="top">44</td>
<td class="Botrule Rrule" align="center" valign="top">62</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-8" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.76 (0.69-0.83)</td>
<td class="Botrule Rrule" align="center" valign="top">152</td>
<td class="Botrule Rrule" align="center" valign="top">199</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Overall Mortality
                                 </td>
<td class="Botrule Rrule" align="center" valign="top">1.00 (0.83-1.19)</td>
<td class="Botrule Rrule" align="center" valign="top">52</td>
<td class="Botrule Rrule" align="center" valign="top">52</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Global Index
                                 </td>
<td class="Rrule" align="center" valign="top">1.13 (1.02-1.25)</td>
<td class="Rrule" align="center" valign="top">184</td>
<td class="Botrule Rrule" align="center" valign="top">165</td>
</tr>
</tbody>
</table>
<p> Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50-59 years of age, a non-significant trend toward reduced risk for overall mortality <span class="Italics">[HR 0.69 (95 percent CI, 0.44-1.07)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb516697-ae78-41d8-b105-6affd8ae611b"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Women’s Health Initiative Memory Study</h2>
<p class="First">The estrogen-alone Women’s Health Initiative Memory Study (WHIMS), an ancillary study of WHI, enrolled 2,947 predominately healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45 percent were 65 to 69 years of age; 36 percent were 70 to 74 years of age; 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 - 2.66).</p>
<p>The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer's disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the treatment and placebo groups was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">see Warnings and Precautions (5.4)</a>, and <a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">Use in Specific Populations (8.5)</a>]</span>.</p>
<p>The WHIMS estrogen plus progestin substudy enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age; 35 percent were 70 to 74 years; 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 4 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE (0.625 mg) plus MPA (2.5 mg) versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE (0.625 mg) plus MPA (2.5 mg) versus placebo was 45 versus 22 per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the treatment and placebo groups was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">see Warnings and Precautions (5.4)</a>, and <a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">Use in Specific Populations (8.5)</a>]</span>.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI, 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[<a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">see Warnings and Precautions (5.4)</a>, and <a href="#i4i_geriatric_use_id_0fd3cfec-0e3c-40da-9582-fd6db60023c6">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_ccd09c00-ecbb-4688-b950-21e792698945"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span>. <span class="Italics">JAMA</span>. 2007; 297:1465-1477.</li>
<li>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. <span class="Italics">Arch Int Med</span>. 2006; 166:357-365.</li>
<li>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span> and Conjugated Equine Estrogen in Women Without a Uterus. <span class="Italics">Arch Int Med</span>. 2006; 166:772-780.</li>
<li>Cushman M, et al. Estrogen Plus Progestin and Risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span>. <span class="Italics">JAMA</span>. 2004; 292:1573-1580.</li>
<li>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <span class="Italics">JAMA</span>. 2006; 295:1647-1657.</li>
<li>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <span class="Italics">JAMA</span>. 2003; 289:3234-3253.</li>
<li>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic cancers and Associated Diagnostic Procedures. <span class="Italics">JAMA</span>. 2003; 290:1739-1748.</li>
<li>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> and Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> in Postmenopausal Women. <span class="Italics">JAMA</span>. 2004; 291:2947-2958.</li>
<li>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. <span class="Italics">J Bone Miner Res</span>. 2006; 21:817-828.</li>
<li>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the Women's Health Initiative. <span class="Italics">Circulation</span>. 2006; 113:2425-2434.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_00d6c4ca-3299-4239-85f3-0581be54b618"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_duplicate_id_0fef668a-ff3a-4ffe-8b63-8eaf1a471d3b"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Each Vagifem (estradiol vaginal tablets), 10 mcg is contained in a disposable, single-use applicator, packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. Cartons contain 8 or 18 applicators with inset tablets.</p>
<p>Vagifem 10 mcg </p>
<p>8 applicators: NDC 54868-6182-0</p>
<p></p>
<p>Keep out of reach of children</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_78595494-c61c-44a2-b10e-9fd6b4e7e371"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 25ºC (77ºF), excursions permitted to 15ºC-30ºC (59ºF-86ºF). Do not refrigerate.</p>
<p>[See USP Controlled Room Temperature.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_43eb0614-a94a-4d6f-956a-dfb6cb30768c"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[<a href="#i4i_patient_package_insert_id_ad577fb7-3c0f-477b-a949-8e2d1d00fd55">See Section 17.5 FDA-APPROVED PATIENT LABELING</a>]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b11ec05-f062-4479-865b-21442f526506"></a><a name="section-16.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></h2>
<p class="First">Inform postmenopausal women of the importance of reporting <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[<a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">see Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_041b9a83-bef0-4981-92c5-5d1419b806b7"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Possible Serious Adverse Reactions with Estrogens</h2>
<p class="First">Inform postmenopausal women of possible serious adverse reactions of estrogen therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, Malignant Neoplasms, and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <span class="Italics">[<a href="#i4i_section_id_eebe6a58-beac-4fbd-b51e-dc248c5d8ae3">see Warnings and Precautions (5.2</a>, <a href="#i4i_section_id_1e34de57-6158-41cd-a1c3-f557a8fb57a5">5.3</a>, <a href="#i4i_section_id_6bfdfda4-beca-49b7-8ea0-4cf6f6988708">5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_093558c6-5da6-484d-8380-b29bcca2dd4b"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Possible Less Serious But Common Adverse Reactions with Estrogens</h2>
<p class="First">Inform postmenopausal women of possible less serious but common adverse reactions of estrogen therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b416697-d695-4456-b88c-66f16f743db0"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Instructions for Use of Applicator</h2>
<p class="First"><span class="Bold">Step 1:</span> Tear off a single applicator.</p>
<p><span class="Bold">Step 2:</span> Separate the plastic wrap and remove the applicator from the plastic wrap as shown in Figure A.</p>
<div class="Figure">
<img alt="Removing applicator from packaging" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-02.jpg"><p class="MultiMediaCaption">Figure A</p>
</div>
<p><span class="Bold">Step 3: </span>Hold  the applicator so that the finger of one hand can press the applicator plunger  as shown in  Figure B.</p>
<div class="Figure">
<img alt="Pressing the applicator plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-03.jpg"><p class="MultiMediaCaption">Figure B</p>
</div>
<p><span class="Bold">Step 4:</span> Next select the best position for vaginal insertion of Vagifem (estradiol vaginal tablets) that is most comfortable for you. See suggested reclining Figure C or standing Figure D position illustrated below:</p>
<div class="Figure">
<img alt="Application via reclining position" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-04.jpg"><p class="MultiMediaCaption">Figure C</p>
</div>
<div class="Figure">
<img alt="Application via standing position" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-05.jpg"><p class="MultiMediaCaption">Figure D</p>
</div>
<p><span class="Bold">Step 5: </span>Using  the other hand, guide the applicator gently and comfortably through the vaginal opening (see Figures C and D above). <span class="Underline">If the tablet has come out of the applicator prior to insertion, carefully put it back into the applicator for insertion. Please keep your hands clean while handling the tablet.</span></p>
<p><span class="Bold">Step 6: </span>The applicator should be inserted (without forcing) as far as comfortably possible, or until half of the applicator is inside your vagina, whichever is less.</p>
<p><span class="Bold">Step 7:</span> Once the tablet-filled applicator has been inserted, gently press the plunger until the plunger is fully depressed. This will eject the tablet inside your vagina where it will dissolve slowly over several hours.</p>
<p><span class="Bold">Step 8: </span>After depressing the plunger, gently remove the applicator and dispose of it the same way you would a plastic tampon applicator. The applicator is of no further use and should be discarded properly. Insertion may be done at any time of the day. It is advisable to use the same time daily for all applications of Vagifem (estradiol vaginal tablets). If you have any questions, please consult your healthcare provider or pharmacist.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_ad577fb7-3c0f-477b-a949-8e2d1d00fd55"></a><a name="section-17"></a><p></p>
<h1>17.5 FDA-Approved Patient Labeling</h1>
<p class="First"><span class="Bold">Vagifem<span class="Sup">® </span>(estradiol vaginal tablets)</span></p>
<p>Read this PATIENT INFORMATION before you start using Vagifem and read the patient information each time you refill your Vagifem prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span> and their treatment.</p>
<div class="Warning">
<a name="id_1ff790ab-326b-473a-820e-b730662b5f6e"></a><a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">What is the most important information I should know about VAGIFEM</span></p>
<p><span class="Bold">(an estrogen hormone)</span></p>
<ul><li>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb)</li></ul>
<p>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are using Vagifem. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find the cause.</p>
<ul>
<li>Do not use estrogen-alone to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (decline of brain function)</li>
<li>Using estrogen-alone may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots</li>
<li>Using estrogen-alone may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women age 65 years or older</li>
<li>Do not use estrogens with progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></li>
<li>Using estrogens with progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, or blood clots</li>
<li>Using estrogens with progestin may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years and older</li>
<li>You and your healthcare provider should talk regularly about whether you still need treatment with Vagifem</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a3468fc-1dd4-496e-8b52-305d14f6343c"></a><a name="section-17.1"></a><p></p>
<p class="First"><span class="Bold">What is Vagifem?</span></p>
<p>Vagifem is a medicine that contains estradiol (an estrogen hormone) in a vaginal tablet.</p>
<p><span class="Bold">What is Vagifem used for?</span></p>
<p>Vagifem is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<ul><li>Treat menopausal changes in and around the vagina</li></ul>
<p>You and your healthcare provider should talk regularly about whether you still need treatment with Vagifem to control these problems.</p>
<p><span class="Bold">Who should not use Vagifem?</span></p>
<p>Do not start using Vagifem if you:</p>
<ul><li><span class="Bold">Have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></li></ul>
<ul><li><span class="Bold">Currently have or have had certain cancers</span></li></ul>
<p>Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have, have had or suspect cancer, talk with your healthcare provider about whether you should use Vagifem.</p>
<ul><li><span class="Bold">Had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></span></li></ul>
<ul><li><span class="Bold">Currently have or have had blood clots</span></li></ul>
<ul><li><span class="Bold">Currently have or have had liver problems</span></li></ul>
<ul><li><span class="Bold">Are allergic to <span class="Bold">Vagifem or </span>any of its ingredients </span></li></ul>
<p>See the list of ingredients in Vagifem at the end of this leaflet.</p>
<ul><li><span class="Bold">Think you may be pregnant</span></li></ul>
<p><span class="Bold">Tell your health care provider:</span></p>
<ul><li><span class="Bold">If you have any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></span></li></ul>
<p><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find the cause. </p>
<ul><li><span class="Bold">About all of your medical problems</span></li></ul>
<p>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</p>
<ul><li><span class="Bold">About all the medicines you take</span></li></ul>
<p>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how Vagifem works. Vagifem may also affect how your other medicines work.</p>
<ul><li><span class="Bold">If you are going to have surgery or will be on bed rest</span></li></ul>
<p>You may need to stop using Vagifem.</p>
<ul><li><span class="Bold">If you are breast feeding </span></li></ul>
<p>The hormone in Vagifem can pass into your milk.</p>
<p><span class="Bold">How should I use Vagifem?</span></p>
<p>Vagifem is a tablet that you place in your vagina with an applicator.</p>
<ul>
<li>Take the dose recommended by your healthcare provider and talk to him or her about how well that dose is working for you</li>
<li>Estrogens should be used at the lowest dose possible for your treatment only as long as needed</li>
</ul>
<p>You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with Vagifem.</p>
<p><span class="Bold">Step 1:</span> Tear off a single applicator.</p>
<p><span class="Bold">Step 2:</span> Separate the plastic wrap and remove the applicator from the plastic wrap as shown in Figure A.</p>
<div class="Figure">
<img alt="Removing applicator from packaging" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-06.jpg"><p class="MultiMediaCaption">Figure A</p>
</div>
<p><span class="Bold">Step 3: </span>Hold  the applicator so that the finger of one hand can press the applicator plunger  as shown in  Figure B.</p>
<div class="Figure">
<img alt="Pressing the applicator plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-07.jpg"><p class="MultiMediaCaption">Figure B</p>
</div>
<p><span class="Bold">Step 4:</span> Next select the best position for vaginal insertion of Vagifem (estradiol vaginal tablets) that is most comfortable for you. See suggested reclining Figure C or standing Figure D position illustrated below:</p>
<div class="Figure">
<img alt="Application via reclining position" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-08.jpg"><p class="MultiMediaCaption">Figure C</p>
</div>
<div class="Figure">
<img alt="Application via standing position" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=71ea0694-1c92-4ec6-8174-a669217aec65-09.jpg"><p class="MultiMediaCaption">Figure D</p>
</div>
<p><span class="Bold">Step 5: </span>Using  the other hand, guide the applicator gently and comfortably through the vaginal opening (see Figures C and D above). <span class="Underline"><span class="Underline">If the tablet has come out of the applicator prior to insertion, carefully put it back into the applicator for insertion. Please keep your hands clean while handling the</span> tablet.</span></p>
<p><span class="Bold">Step 6: </span>The applicator should be inserted (without forcing) as far as comfortably possible, or until half of the applicator is inside your vagina, whichever is less.</p>
<p><span class="Bold">Step 7:</span> Once the tablet-filled applicator has been inserted, gently press the plunger until the plunger is fully depressed. This will eject the tablet inside your vagina where it will dissolve slowly over several hours.</p>
<p><span class="Bold">Step 8: </span>After depressing the plunger, gently remove the applicator and dispose of it the same way you would a plastic tampon applicator. The applicator is of no further use and should be discarded properly. Insertion may be done at any time of the day. It is advisable to use the same time daily for all applications of Vagifem (estradiol vaginal tablets). If you have any questions, please consult your healthcare provider or pharmacist.</p>
<p><span class="Bold">Dosage</span></p>
<p>Vagifem therapy consists of the following dosing regimen:</p>
<p>One (1) Vagifem tablet inserted vaginally once daily for the first two (2) weeks, then one (1) tablet inserted twice weekly (for example Tuesday and Friday) for as long as you use Vagifem.</p>
<p><span class="Bold">What are the possible side effects of Vagifem?</span></p>
<p>Vagifem is only used in the vagina; however, the risks associated with oral estrogens should be taken into account.</p>
<p><span class="Bold">Side effects are grouped by how serious they are and how often they happen when you are treated.</span></p>
<p><span class="Bold">Serious but less common side effects include:</span></p>
<ul>
<li>Breast cancer</li>
<li>Cancer of the uterus </li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span></li>
<li>Blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li>Ovarian cancer</li>
<li>High blood pressure</li>
<li>Liver problems</li>
<li>High blood sugar</li>
<li>Enlargement of benign tumors of the uterus (“fibroids?) </li>
</ul>
<p><span class="Bold">Some of the warning signs of serious side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span></li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness</li>
<li>Changes in speech</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs</li>
<li>Changes in vision</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li>Yellowing of the skin, eyes or nail beds</li>
</ul>
<p>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptoms that concern you.</p>
<p><span class="Bold">Less serious, but common, side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span> </li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
</ul>
<p>These are not all the possible side effects of Vagifem. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with Vagifem?</span></p>
<ul>
<li>Talk with your healthcare provider regularly about whether you should continue using Vagifem</li>
<li>If you have a uterus, talk with your healthcare provider about whether the addition of a progestin is right for you</li>
</ul>
<p>The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus. See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while using Vagifem.</p>
<ul><li>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else</li></ul>
<p>If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often.</p>
<ul><li>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease</li></ul>
<p>Ask your healthcare provider for ways to lower your chances for getting heart disease.</p>
<p><span class="Bold">General information about the safe and effective use of Vagifem.</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Vagifem for conditions for which it was not prescribed. Do not give Vagifem to other people, even if they have the same symptoms you have. It may harm them. <span class="Bold">Keep Vagifem out of the reach of children.</span></p>
<p>This leaflet provides a summary of the most important information about Vagifem. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about Vagifem that is written for health professionals. You can get more information by calling the toll free number 1-888-824-4336.</p>
<p><span class="Bold">What are the ingredients in Vagifem?</span></p>
<p>Vagifem (estradiol vaginal tablets) are small, white, film-coated tablets containing estradiol. Each tablet also contains hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol.</p>
<p>Each Vagifem tablet is contained in a disposable applicator, packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. Cartons contain 8 or 18 applicators with inset tablets.</p>
<p><span class="Bold">Store at 25ºC (77ºF); excursions permitted to 15ºC - 30ºC (59ºF - 86ºF). Do not refrigerate. </span></p>
<p><span class="Bold">[see USP Controlled Room Temperature].</span></p>
<p><span class="Italics">Vagifem<span class="Sup">®</span> is a registered trademark owned by Novo Nordisk FemCare AG</span>.</p>
<p>© 2003-2011 Novo Nordisk </p>
<p>Date of Issue: May 18, 2011</p>
<p>Version: 7</p>
<p>For Information contact:</p>
<p>Novo Nordisk Inc.</p>
<p>100 College Road West</p>
<p>Princeton, NJ 08540, USA</p>
<p>1-888-824-4336</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>2880 Bagsvaerd, Denmark</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17.2"></a><p></p>
<p class="First"><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0e82724e-f1ff-47e4-bef9-f563ec68abf9"></a><a name="section-18"></a><p></p>
<h1>Principal Display panel - VAGIFEM 10 <span class="Bold">MCG</span>
</h1>
<p class="First">NDC 54868-6182-0</p>
<p><span class="Bold">Vagifem<span class="Sup">®</span> 10mcg</span></p>
<p><span class="Bold">(estradiol vaginal tablets)</span></p>
<p>8 vaginal tablets</p>
<div class="Figure"><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d67888ac-5041-4758-88db-845a41f67df4&amp;name=6182.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VAGIFEM 		
					</strong><br><span class="contentTableReg">estradiol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6182(NDC:0169-5176)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">10 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">54.212 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6182-0</td>
<td class="formItem">8  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020908</td>
<td class="formItem">09/24/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ad9ebd92-2d74-4cac-aea3-3c33d3a9f116</div>
<div>Set id: d67888ac-5041-4758-88db-845a41f67df4</div>
<div>Version: 2</div>
<div>Effective Time: 20120315</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
